In the adjuvant setting, the IMpower010 trial showed that atezolizumab after adjuvant chemotherapy prolonged DFS and OS in patients with PD-L1-positive stage II-IIIA NSCLC (DFS HR 0.70, 95% CI 0.55–0.91 in stage II-IIIA PD-L1 ≥ 1%; DFS HR 0.48, 95% CI 0.32–0.72 in stage II-IIIA PD-L1 ≥ 50%; OS HR 0.71 in PD-L1 ≥ 1%; HR 0.43 in PD-L1 ≥ 50%) [18,19]. Here, CD274 is linked to non-small cell lung carcinoma.